Merck Completes Acquisition Of Harpoon Therapeutics - Quick Facts
Written by Emily J. Thompson, Senior Investment Analyst
Source: Business Insider
- Merck完成收购Harpoon Therapeutics：Merck宣布完成对Harpoon Therapeutics公司的收购，使其成为公司的全资子公司。
- Harpoon不再公开交易：Harpoon的普通股将不再在纳斯达克证券交易所公开交易或上市。
- 交易对预期全年非GAAP每股收益的影响：此次交易对预期2024全年非通用会计准则每股收益的影响约为0.26美元。
- Harpoon的主力候选药物MK-6070：MK-6070是Harpoon的主力候选药物，是一种靶向δ样配体3的T细胞结合剂，该配体在小细胞肺癌和神经内分泌肿瘤中表达水平较高。
- 更多健康新闻：访问rttnews.com获取更多类似的健康新闻。
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
